Regeneron has once again received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the ...
An anti-inflammation injectable drug called dupilumab can reduce mucus buildup and improve breathing among asthma patients, a ...
Use of GLP-1 receptor agonists did not appear to affect esophageal function among patients with type 2 diabetes, according to study results presented at ACG Annual Scientific Meeting.Research has ...
Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...
Regeneron Pharmaceuticals jumped 12% after delivering upbeat guidance yesterday, its second-best advance in more than three ...
Regeneron investors should embrace the fact that Eylea is no longer a growth product and focus on the rest of the commercial ...
The FDA is planning to speed approvals of highly similar copies of expensive biologic drugs, the latest effort in President ...
Regeneron will be responsible for funding preclinical, clinical and commercial development for any ModeX product it chooses to advance from the research pact, with ModeX eligible for milestone ...
In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.51%, the company may face hurdles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback